Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - lamotrigine, quantity: 200 mg - tablet, chewable - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; aspartame; hyprolose; purified talc; colloidal anhydrous silica; magnesium stearate; maltodextrin; calcium carbonate; flavour - noumed lamotrigine is an antiepileptic drug for the treatment of partial and generalized seizures in adults and children. there is extensive experience with lamotrigine used initially as "add-on" therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - lamotrigine, quantity: 100 mg - tablet, chewable - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; aspartame; hyprolose; purified talc; colloidal anhydrous silica; magnesium stearate; calcium carbonate; maltodextrin; flavour - noumed lamotrigine is an antiepileptic drug for the treatment of partial and generalized seizures in adults and children. there is extensive experience with lamotrigine used initially as "add-on" therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - lamotrigine, quantity: 50 mg - tablet, chewable - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; aspartame; hyprolose; purified talc; colloidal anhydrous silica; magnesium stearate; calcium carbonate; maltodextrin; flavour - noumed lamotrigine is an antiepileptic drug for the treatment of partial and generalized seizures in adults and children. there is extensive experience with lamotrigine used initially as "add-on" therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - lamotrigine, quantity: 25 mg - tablet, chewable - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; aspartame; hyprolose; purified talc; colloidal anhydrous silica; magnesium stearate; calcium carbonate; maltodextrin; flavour - noumed lamotrigine is an antiepileptic drug for the treatment of partial and generalized seizures in adults and children. there is extensive experience with lamotrigine used initially as "add-on" therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - furosemide, quantity: 40 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; maize starch; lactose monohydrate; magnesium stearate; sodium starch glycollate - oedema: adults. treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome. noumed furosemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. hypertension: adults. noumed furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with noumed furosemide alone.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - mirtazapine, quantity: 45 mg - tablet, film coated - excipient ingredients: hyprolose; hypromellose; magnesium stearate; lactose monohydrate; titanium dioxide; macrogol 8000; maize starch; colloidal anhydrous silica - treatment of major depression.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - mirtazapine, quantity: 30 mg - tablet, film coated - excipient ingredients: macrogol 8000; hyprolose; iron oxide yellow; colloidal anhydrous silica; iron oxide red; iron oxide black; hypromellose; magnesium stearate; titanium dioxide; maize starch; lactose monohydrate - treatment of major depression.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - escitalopram oxalate, quantity: 25.54 mg (equivalent: escitalopram, qty 20 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; hypromellose; titanium dioxide; microcrystalline cellulose; macrogol 6000; purified talc; croscarmellose sodium; magnesium stearate; lactose monohydrate - treatment of major depression. treatment of obsessive compulsive disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - escitalopram oxalate, quantity: 12.77 mg (equivalent: escitalopram, qty 10 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; purified talc; hypromellose; macrogol 6000; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; lactose monohydrate; titanium dioxide - treatment of major depression. treatment of obsessive compulsive disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: meglumine; magnesium stearate; lactose; sodium hydroxide; povidone; lactose monohydrate; crospovidone - noumed telmisartan is indicated for: - treatment of hypertension - prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)